| Vol. 14.24 – 30 June, 2022 |
| |
|
|
| Scientists established a general operation process for obtaining high-quality clinical-grade cell subpopulations from human umbilical cord MSCs based on particular markers. [Cell Proliferation] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers studied the attachment and proliferation of human umbilical cord-MSCs (HUMSCs) on alginate-gelatin core-shell microcarriers with different mechanical strengths modulated by gelatin coating, and the harvested cells were characterized to verity their differentiation potential. [International Journal of Biological Macromolecules] |
|
|
|
| Investigators identified natural small extracellular vesicles harvested from Wharton’s jelly MSCs. [International Journal of Pharmaceutics] |
|
|
|
| Researchers compared transplantation outcomes of adult patients with acute myeloid leukemia that underwent CBT in CR1 following one versus two induction courses. [Bone Marrow Transplantation] |
|
|
|
| Plasmacytoma variant translocation 1 (PVT1), miR-24-3p, and HSD11B2 expression levels in normal placental tissues and preeclampsia placental tissues were defined. [Molecular Reproduction and Development] |
|
|
|
| Umbilical cord-derived-MSCs and adipose-derived-MSC were isolated from the umbilical cord and subcutaneous fatty tissue of humans respectively and identified by flow cytometry. [Acta Histochemica] |
|
|
|
|
| The authors outline the current understanding of placental development, and critically consider the range of established and emerging culture models used to study this, with a focus on those derived from primary tissue. [Cellular and Molecular Life Sciences] |
|
|
|
|
| BioRestorative Therapies, Inc. announced that the first patient has been enrolled in the company’s Phase II clinical trial evaluating the safety and preliminary efficacy of BRTX-100, an autologous bone marrow-derived mesenchymal stem cell targeting chronic lumbar disc disease. [BioRestorative Therapies, Inc. (GlobeNewswire, Inc.)] |
|
|
|
|
| December 8 – 10, 2022 Los Angeles, California, United States |
|
|
|
|
|
| University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| Boston Children’s Hospital – Boston, Massachusetts , United States |
|
|
|
| Van Andel Institute – Grand Rapids, Michigan, United States |
|
|
|
| Flanders Institute for Biotechnology – Antwerp, Belgium |
|
|
|
|